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Isoniazid (INH), the mainstay therapeutic for tuberculosis infec-
tion, has been associated with rare but serious hepatotoxicity in the
clinic. However, the mechanisms underlying inter-individual vari-
ability in the response to this drug have remained elusive. A ge-
netically diverse mouse population model in combination with a
systems biology approach was utilized to identify transcriptional
changes, INH-responsive metabolites, and gene variants that con-
tribute to the liver response in genetically sensitive individuals.
Sensitive mouse strains developed severe microvesicular steatosis
compared with corresponding vehicle control mice following 3 days
of oral treatment with INH. Genes involved in mitochondrial dys-
function were enriched among liver transcripts altered with INH
treatment. Those associated with INH treatment and susceptibility
to INH-induced steatosis in the liver included apolipoprotein A-IV,
lysosomal-associated membrane protein 1, and choline phospho-
transferase 1. These alterations were accompanied by metabolomic
changes including reduced levels of glutathione and the choline
metabolites betaine and phosphocholine, suggesting that oxida-
tive stress and reduced lipid export may additionally contribute to
INH-induced steatosis. Finally, genome-wide association mapping
revealed that polymorphisms in perilipin 2 were linked to increased
triglyceride levels following INH treatment, implicating a role for
inter-individual differences in lipid packaging in the susceptibil-
ity to INH-induced steatosis. Taken together, our data suggest that
INH-induced steatosis is caused by not one, but multiple events in-
volving lipid retention in the livers of genetically sensitive individ-
uals. This work also highlights the value of using a mouse diversity
panel to investigate drug-induced responses across a diverse pop-
ulation.
Tuberculosis (TB) is a life-threatening disease arising from
Mycobacterium tuberculosis infection and the second leading
cause of death worldwide (WHO, 2013). Although TB carries
a high mortality rate, in part due to inaccessibility to therapeu-
tics or noncompliance, the infection is curable with appropri-
ate treatment. The mainstay therapeutic for treatment is isoni-
azid (INH), a potent bactericidal agent recognized as an effec-
tive therapy for TB since its introduction in 1952 (Jindani et al.,
1980).
Clinical evidence has long demonstrated that INH can cause
adverse side effects. These adverse responses reduce treatment
efficacy by decreasing compliance, resulting in treatment fail-
ure, relapse, and/or drug resistance (Kopanoff et al., 1978).
Hepatotoxicity is the predominant adverse side effect, with a
high proportion of patients (approximately 10–20%) experi-
encing mild, transient elevations in aminotransferase levels. In
rare instances, INH treatment has been associated with cases of
acute liver failure with features of hepatitis and hepatic necro-
sis occurring at an incidence of 0.1–1% (Fountain et al., 2005;
Kopanoff et al., 1978). There have also been case reports in-
dicating that steatosis is present in livers of patients with hep-
atotoxicity arising from TB drug treatments that included INH
(Pilheu et al., 1979; Pilheu et al., 1981). However, biopsies are
not routinely taken for patients with liver injury and the inci-
dence of INH-induced steatosis is not known.
The production of reactive metabolites from INH such as
acetylhydrazine (Nelson et al., 1976) and hydrazine (Sarich
et al., 1996) have been proposed to contribute to the toxicity.
Changes in the liver metabolite profile with INH treatment may
also occur due to INH-induced depletion of pyridoxal phosphate
(PLP) (Sumner et al., 2010). However, the exact characteristics
of idiosyncratic INH-induced hepatotoxicity have been chal-
lenging to reproduce in animal models. As result, the mecha-
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nisms associated with INH-induced liver injury are not well un-
derstood (Metushi et al., 2011).
Genetics is now recognized as a key factor in the toxi-
city and efficacy of pharmaceutical agents. Susceptibility to
INH-induced hepatotoxicity has been linked with genetic fac-
tors such as the absence of HLA-DQA1*0102; the presence
of HLA-DQB1*0201 alleles (Sharma et al., 2002); and poly-
morphisms in cytochrome P450 2E1 (CYP2E1), glutathione S-
transferase mu 1 (GSTM1), and glutathione S-transferase theta
1 (GSTT1) (Tostmann et al., 2008). Slow acetylator variants of
N-acetyltransferase 2 that reduce the metabolism of isoniazid to
acetylisoniazid, and subsequently acetylhydrazine to the non-
toxic metabolite diacetylhydrazine, may also contribute to INH
toxicity (Huang et al., 2002). However, the predictive value and
effect sizes of these markers in clinical practice have been low,
indicating that additional factors must be required to influence
susceptibility to INH-induced hepatotoxicity.
A mouse diversity panel (MDP) is a commercially available
panel of well-characterized, inbred mouse strains (Bogue and
Grubb, 2004; McClurg et al., 2007) with genetic diversity com-
parable with that observed in humans (Roberts et al., 2007).
When strain-specific responses can be measured, an MDP can
be utilized to elucidate the genetic basis for toxicity. An MDP
has been used successfully to model drug-induced kidney in-
jury resulting from treatment with DB289, a drug that caused
renal toxicity in clinical trials that was not predicted in nonclin-
ical safety studies (Harrill et al., 2012). An MDP was also uti-
lized to identify a genetic variant associated with susceptibility
to acetaminophen-induced liver injury in humans (Court et al.,
2013; Harrill et al., 2009).
In the present study, a systems biology approach, integrating
data obtained from multiple “omic” analyses, was employed to
investigate genetic differences in INH-induced liver response
using an MDP. Pharmacogenomic analysis of transcriptional
changes and gene variants associated with the INH response,
coupled with metabolomics analysis of liver tissue, were uti-
lized to identify factors potentiating INH-induced microvesicu-
lar steatosis in the livers of genetically sensitive mouse strains.
MATERIALS AND METHODS
Animals. Female mice aged 6–8 weeks were purchased
from the Jackson Laboratory (129S1/SvlmJ, A/J, AKR/J,
BALB/cJ, BTBR T+tf/J, BUB/BnJ, C3H/HeJ, C57BL/6J,
C57BLKS/J, C57BR/cdJ, C58/J, CBA/J, CE/J, DBA/2J,
FVB/NJ, I/LnJ, KK/HIJ, LG/J, LP/J, MA/MyJ, MRL/MpJ,
NOD/ShiLtJ, NON/ShiLtJ, NOR/LtJ, NZW/LacJ, P/J,
PL/J, PWK/PhJ, RIIIS/J, SEA/GnJ, SJL/J, SM/J, SWR/J,
WSB/EiJ) and housed in polycarbonate cages on a 12-h
light-dark cycle in a specific-pathogen free facility. Mice were
provided NIH-07 diet (Zeigler Brothers) ad libitum, with the
exception of an 18-h fast preceding drug treatment (for liver
glutathione depletion) and an additional 18-h fast immediately
prior to euthanasia (for liver glycogen depletion). Care of mice
followed institutional guidelines under a protocol approved
by The Hamner Institutes’ Institutional Animal Care and Use
Committee.
Experimental design. Mice were randomized by body weight
into treatment groups (N = 4 per group per strain) and dosed in-
tragastrically (ig) with 100 mg/kg INH (Fisher Scientific) or
vehicle (sterile water) once daily for 3 days in a dosing vol-
ume of 10 ml/kg. The first day of dosing was designated as day
1. Dosing was performed at the same time of day throughout
the study to avoid diurnal variability. On day 4, animals were
weighed and administered an intraperitoneal (i.p.) injection of
pentobarbital sodium (150 mg/kg) to induce deep anesthesia.
Blood was collected via cardiac puncture. Livers were quickly
excised and weighed. Sections of the left liver lobe were placed
in 10% phosphate buffered formalin for histological analyses.
The remaining tissue was snap-frozen in liquid nitrogen and
stored at −80oC.
Of the 272 animals included in the initial study, 13 INH-
treated animals died prematurely; these animals were therefore
excluded from data analysis. Animals (and total number) that
were excluded came from the following strains: LP/J (one),
PL/J (one), SM/J (two), NON/LtJ (one), LG/J (one), MA/MyJ
(two), RIIIS/J (one), SEA/GnJ (two), A/J (two). The majority
of INH-treated P/J and WSB/EiJ animals died prematurely in
the study and therefore these strains were not included in sub-
sequent analyses. The cause of death was not determined, but
was not attributed to liver injury, and was not associated with
preceding clinical symptoms.
Liver histopathology. Formalin-fixed liver tissue was
paraffin-embedded, cut into 5-m sections, and stained with
hematoxylin and eosin (H&E). H&E stained slides were
microscopically examined and scored by a certified veterinary
pathologist blinded to treatment (Experimental Pathology
Laboratories, Inc.). Significance was assessed between control
and treated animals of the same strain. The following grading
guidelines were applied to histopathologic findings in this
project: Grade 0: none, Grade 1: minimal, Grade 2: slight/mild,
Grade 3: moderate, Grade 4: moderately severe, Grade 5:
severe/high.
Adipophilin immunohistochemistry. Five micron sections
were cut from formalin-fixed, paraffin-embedded liver tissue
and mounted on positively charged microscopic slides. Paraffin
was removed and slides hydrated by passing through a series
of xylenes and graded alcohols to distilled water. Sections were
then pre-treated with a citrate buffer, pH 6.0 (Chemicon) using a
vegetable steamer at 96◦C for 20 min. Slides were removed and
cooled on the lab bench for an additional 20 min. All immuno-
histochemical steps were performed on an automated Dako Au-
tostainer. Endogenous peroxidase was blocked by incubation in
3.0% hydrogen peroxide (aq) for 10 min, whereas endogenous
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biotin was blocked utilizing Dako’s Biotin Blocking System.
Additional blocking steps included a 20-min incubation with
Dako serum-free protein block. Guinea pig anti-adipohilin anti-
body (Progen) was applied at a dilution of 1:10,000 for 60 min at
room temperature. Additional slides were processed using anti-
body diluent without the adipophilin antibody as a negative con-
trol. A biotinylated goat anti-guinea pig IgG antibody (Vector
Laboratories) was applied at a dilution of 1:150 for 45 min fol-
lowed by detection with Vector’s Elite ABC kit for 30 min. Pos-
itive staining was visualized using Dako’s Liquid DAB+ for 5
min. Slides were scanned on a Hamamatsu Nanozoomer whole
slide digital scanner and images were evaluated by a certified
veterinary pathologist who was blinded to treatment (Pfizer).
Liver triglyceride measurements. Liver triglyceride levels
were quantified using approximately 50 mg of frozen tissue ob-
tained from the left lobe of the liver homogenized in a solu-
tion of 5% NP-40. Twice homogenized tissue was heated to 80–
100◦C until NP-40 became cloudy and then cooled to room tem-
perature. Following this cycle of heating and cooling, samples
were centrifuged to remove debris and diluted (1:10) in dH2O.
Diluted samples were assayed with the Triglyceride Quantifica-
tion Kit (AbCam) using the manufacturer’s recommendations.
Gene expression analysis. RNA was isolated from approxi-
mately 15 mg of liver tissue using an RNeasy total RNA iso-
lation kit (Qiagen) according to manufacturer’s instructions.
RNA was quantified on a NanoDrop ND-1000 spectropho-
tometer (Thermo Scientific) and quality was verified with an
Agilent 2100 Bioanalyzer (Agilent Technologies). RNA was
determined to be of good quality for use in microarray hy-
bridizations if the RNA integrity number was 8 or higher. The
GeneChip 3′ IVT Express Kit (Affymetrix) was utilized to gen-
erate fragmented, biotin-labeled aRNA which was subsequently
hybridized to the GeneChip Mouse Genome 430 2.0 Array using
the GeneChip Hybridization, Wash, and Stain Kit (Affymetrix)
according to manufacturer’s instructions. Following hybridiza-
tion, arrays were washed and stained using standard Affymetrix
procedures before scanning on an Affymetrix GeneChip Scan-
ner.
Due to the potential for single-nucleotide polymorphisms
(SNPs) across the MDP to affect microarray probe binding and
confound expression analysis (Alberts et al., 2007), individual
probes overlapping SNPs in the inbred strains were removed
from the dataset prior to analysis. Briefly, Affymetrix Mouse
Genome 430 2.0 probe sequences were aligned to the NCBI
Build 37 version of the mouse genome as part of the AceView
annotation project (Thierry-Mieg and Theirry-Mieg, 2006), and
genomic locations were downloaded from AceView (http://
www.ncbi.nlm.nih.gov/IEB/Research/Acembly/; version from
24 April 2008). Probes overlapping SNPs in the MDP strains
were identified using the SNPtools package (version 1.01) in
R (http://cran.r-project.org) and removed from further analy-
sis. Remaining intensity ratios were RMA (Robust Multi-array
Analysis) transformed using the Affymetrix Power Tools (APT
version 1.14.2) program, apt-probeset-summarize. Array data
were then analyzed using Partek Genomics Suite (version 6.6).
Pathways enriched among statistically significant (p < 0.05),
differentially expressed genes in the data were identified us-
ing the Tox Analysis module in Ingenuity Pathway Analysis
(Ingenuity Systems; Build version: 261899; Content version:
17199142). High-quality RNA could not be isolated from the
liver of I/LnJ animals, therefore this strain was excluded from
the microarray analysis. Gene expression data generated for this
manuscript can be downloaded in its entirety from the Gene
Expression Omnibus repository under the accession number
GSE55489. All data are MIAME compliant.
Metabolomics. INH- and vehicle-treated animals from three
drug-sensitive mouse strains with INH-induced steatosis sever-
ity scores of 2–5 (NOR/LtJ, DBA/J, and LG/J), and two strains
with INH-induced steatosis severity scores of 0–1 (NON/ShiLtJ
and C57BR/cdJ), were selected for analysis of metabolites in
liver tissue. Sample preparation, data acquisition, and process-
ing for metabolomic analysis were carried out as consistent with
previous studies (Sumner et al., 2010). Data were acquired on
a Bruker Avance III 700 MHz Nuclear Magnetic Resonance
(NMR) spectrometer equipped with a cryoprobe, and a Bruker
SampleJet autosampler. Briefly, 1H NMR spectra were acquired
using the first increment of a NOESY sequence, with a 100 ms
mixing time, 2 s relaxation delay, a spectral width of 16 ppm,
32,768 data points, and 32 transients. Raw NMR data were pro-
cessed by applying a line broadening factor of 0.5 Hz to the
free induction decay, zero filling to double the data points to ap-
proximately 64,000, and applying Fourier transformation after
exponential multiplication. Processed NMR data were binned
by steatosis severity score (low or high), and the integrals were
normalized to the total intensity of each spectrum. Multivariate
analysis of binned data was performed using orthogonal partial
least squares discriminant analysis (OPLS-DA) using SIMCA
13.0 (Umetrics), and statistical significance was determined us-
ing a Student’s t-test.
Liver and serum cholesterol measurements. Liver choles-
terol and serum LDL/VLDL levels were measured in the same
animals used for the metabolomics experiments. Liver choles-
terol was measured with the Advia 2400 clinical chemistry an-
alyzer utilizing the Cholesterol 2 Reagent (Siemens Healthcare
Diagnostic Inc.) according to the manufacturer’s recommenda-
tions. Serum LDL/VLDL was measured using the EnzyChrom
AF HDL and LDL/VLDL Assay Kit (BioAssay Systems) ac-
cording to manufacturer’s instructions.
Quantitative Trait Locus mapping. Quantitative Trait Locus
(QTL) mapping was performed using SNPster, which incorpo-
rates a haplotype mapping approach over inferred three-SNP
haplotypes (McClurg et al., 2007). Triglyceride fold change was
mapped using a 623,046 SNP dataset, and all data were log
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transformed prior to analysis. The association scores, –log(p)
values, from the analysis were plotted across the mouse genome
using the RGenetics package in Galaxy (http://main.g2.bx.psu.
edu/, accessed 3 September 2013). Results were reported for
putative QTLs above an arbitrarily defined threshold set at –
log(p) > 3.5. For every putative QTL, corresponding locations
(Mb) were calculated as previously described (McLachlan et al.,
2011). Briefly, each putative QTL was expanded to the left
and right for as long as the association score was >2 (or by
at least 100 kb). If two putative QTLs overlapped or were <1
Mb apart they were considered to be one signal. Quantitative
trait genes (QTGs) were identified with the UCSC Genome
Browser (http://genome.ucsc.edu) using NCBI mouse genome
build 37. SNPs within QTGs were identified using the Imputed
Mouse SNP Resource (http://csbio.unc.edu/imputation/#tools,
accessed 3 September 2013).
Statistical methods. Phenotypic values are expressed as the
mean ± standard error (SE). Differences between treatment
groups, steatosis groups, and genotypes were determined us-
ing a two-tailed Student’s t-test or a Mann Whitney U-test us-
ing GraphPad Prism 5 (GraphPad Software). Statistical out-
comes were considered significant when the p value was <0.05.
Gene expression differences were determined using an analy-
sis of variance (ANOVA) model or linear regression analysis
in Partek Genomics Suite. Analysis of gene expression changes
associated with susceptibility to INH-induced steatosis in the
MDP included the fixed categorical factors of strains (resistant
vs. susceptible to INH-induced steatosis) and treatment (vehicle
vs. INH), as well as the random factor scan date, to control for
batch effects. Statistical outcomes for mRNA expression data
were considered significant when the Bonferroni corrected p
value was <0.05.
RESULTS
INH-Induced Microvesicular Steatosis in Sensitive Inbred
Mouse Strains
Histopathological analysis identified the presence of signifi-
cantly augmented levels of hepatocytic cytoplasmic microvesic-
ulation in 14/32 (44%) strains treated with INH compared with
vehicle-treated controls (Fig. 1A). The variability in the INH-
induced response suggested a genetic contribution to the phe-
notype, and pathological interpretation of these findings iden-
tified the vesiculation as reflective of effects on lipid trans-
port or metabolism and indicative of steatosis. To confirm
this interpretation, adipophilin immunohistochemistry was per-
formed, identifying microvesicles containing neutral lipids, on
the liver sections from all vehicle- and INH-treated animals in
the study. In agreement with the original findings, adipophilin
staining demonstrated a high degree of inter-strain variabil-
ity (Supplementary fig. 1A). Furthermore, severity scores from
the adipophilin-stained slides were significantly correlated with
severity scores derived from the H&E stained slides (Spearman
r = 0.4297, p < 0.0001; Supplementary fig. 1B), thus confirm-
ing the steatotic nature of the microvesicles.
Strains identified as genetically resistant (-) and genetically
sensitive (+) to INH-induced microvesicular steatosis by statis-
tical comparison of severity scores between vehicle- and INH-
treated animals (p < 0.05) are indicated in Figure 1A. Represen-
tative light photomicrographs of the H&E stained liver tissue
illustrating the difference in microvesicular accumulation be-
tween resistant (NON/ShiLtJ) and sensitive (LG/J) strains are
shown in Figure 1B. Sensitivity to INH-induced elevations in
liver triglyceride values also varied by strain (Fig. 1C) and the
values were significantly correlated with the steatosis severity
scores (Spearman r = 0.5143, p <0.0001; Fig. 1D).
As INH is known to inhibit the assay for alanine aminotrans-
ferase, the microRNA (miR) miR-122 was quantified as a sur-
rogate marker for liver injury (Wang et al., 2009). Consistent
with the microscopic findings, which did not indicate serious
liver injury, miR-122 was not significantly elevated with INH
treatment in this study (data not shown).
Determination of Gene Expression Changes Associated with
Treatment and Steatosis
To elucidate the factors contributing to INH-induced steato-
sis, mRNA expression analysis was performed in liver tissue
derived from all vehicle- and INH-treated animals in the study.
An ANOVA model using the fixed categorical factors of strain
(resistant vs. sensitive to INH-induced steatosis; − and + des-
ignated strains from Fig. 1A, respectively) and treatment (vehi-
cle vs. INH) was then applied to the intensity data to determine
which transcripts were significantly altered for each experimen-
tal factor individually or in concert (Fig. 2A). This approach al-
lowed for the identification of genes that distinguish sensitive
and resistant strains, independently of INH treatment, as the re-
sulting gene signatures may play a role in genetic susceptibility
to INH-induced steatosis.
A total of 203 probesets detected differences in mRNA ex-
pression between strains that were genetically resistant or sen-
sitive to INH-induced steatosis (p < 0.05), but for which INH
treatment itself (p > 0.05) did not affect expression, indicating
that these genes differed in basal expression by genetic back-
ground. Canonical pathways enriched among significant genes
in the dataset were identified using the Tox Analysis feature in
IPA. The top enriched pathways are reported in Supplementary
table 1.
A total of 1469 probesets detected expression of mRNAs that
were altered by INH treatment universally, regardless of strain
sensitivity, indicating that these genes are responsive to treat-
ment independent of genetic background. The mitochondrial
dysfunction pathway was the top enriched pathway among these
genes with a −log(p) value of 25.2 (Fig. 2A). A heat map was
used to visualize the gene expression changes of transcripts in
the mitochondrial dysfunction pathway across individual ani-
mals in the different treatment and strain sensitivity categories
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FIG. 1. INH induces inter-strain variations in hepatocytic microvesicular steatosis and triglyceride accumulation. (A) Microvesicular steatosis severity scores
for vehicle- (white circles) and INH-treated (black squares) animals. Data are represented as mean ± SE for N = 4 mice per treatment and strain, except for strains
noted in the Materials and Methods section. Strains are ordered from left to right by increasing average severity score for the INH-treated animals. *p < 0.05
indicates the difference between vehicle- and INH-treated animals. +/- identifies strains sensitive and resistant to INH-induced steatosis as determined by signifi-
cance following a Mann-Whitney U-test. (B) Representative photomicrographs (400X) of liver tissue from vehicle- and INH-treated animals in the NON/ShiLtJ
and LG/J strains. (C) Liver triglyceride (TG) levels for vehicle- (white circles) and INH-treated (black squares) animals. Data are represented as mean ± SE for
N = 4 mice per treatment and strain, except for strains noted in the Materials and Methods section. Strains are ordered from left to right by increasing average
microvesicular steatosis severity scores for the INH-treated animals. *p < 0.05 indicates the difference between vehicle- and INH-treated animals. Significance
was evaluated by a Student’s t-test. (D) Triglyceride concentrations for vehicle- and INH-treated mice were binned according to microvesicular steatosis severity
score. Values represent mean ± SE of liver triglyceride concentrations. Individual means across all strains for each bin were statistically significant (one-way
ANOVA). Post hoc statistical significance was determined using a Tukey’s multiple comparison test. *p < 0.001 indicates the difference relative to severity scores
of 0.
486 CHURCH ET AL.
FIG. 2. Gene expression analysis identifies mitochondrial transcript changes associated with INH treatment. mRNA expression analysis was performed in
liver tissue derived from all vehicle- and INH-treated animals in the study. An ANOVA model using the fixed categorical factors strains (resistant vs sensitive
to INH-induced microveiscular steatosis) and treatment (vehicle vs. INH) was then applied to the intensity data to determine which probesets were significantly
altered by each experimental factor individually or in concert. (A) The number of probesets significantly altered by sensitivity to steatosis and treatment is depicted
in a Venn diagram. Canonical pathways enriched among genes significantly associated with treatment (p < 0.05) but not strains (p > 0.05) were identified using
the Tox Analysis feature in IPA. The top 10 pathways are represented. Relative gene expression changes in the top pathway, mitochondrial dysfunction (bold),
are represented in a heat map. (B) A heat map representing relative gene expression changes the 26 probesets significantly altered by both factors: strains and
treatment. The color scales for both heat maps represent the relative ratio of log2 (intensity).
(Fig. 2A). The majority of the genes in this pathway (94%) were
increased with treatment. Genes significantly altered by treat-
ment included in the mitochondrial dysfunction pathway are de-
scribed in Supplementary table 2.
In order to determine which gene expression changes were
critical for the development of INH-induced steatosis in sensi-
tive strains, the 26 probesets detecting genes significantly al-
tered by both factors—treatment and sensitivity to steatosis—
were then interrogated (Fig. 2B). Due to the low number of
significant genes, pathway analysis using IPA was unproduc-
tive, yielding several pathways that included only a single
gene. Therefore, the list of probesets significantly associated
with treatment and genetic susceptibility to steatosis was man-
ually examined for biologically plausible candidates related
to INH-induced steatosis. Genes involved in lipid metabolism
and export, such as apolipoprotein A-IV (Apoa4), lysosomal-
associated membrane protein 1 (Lamp1), and choline phospho-
transferase 1 (Chpt1) are relevant to the steatosis finding. Rela-
tive to MDP strains resistant to INH-induced steatosis, sensitive
strains had significantly elevated levels of Lamp1 and signifi-
cantly reduced levels of Apoa4 and Chpt1.
Detection of Altered Metabolites Associated with INH-Induced
Steatosis
In order to gain further mechanistic insight into the pro-
cesses underlying INH-induced steatosis, hepatic metabolites
were evaluated in a subset of mouse strains. Liver tissue from
all animals in two drug-resistant strains (steatosis score in
INH-treated animals of 0–1; NON/ShiLtJ, C57BR/cdJ) and
three drug-sensitive strains (steatosis score in INH-treated an-
imals of 2–5; NOR/LtJ, DBA/2J, and LG/J) was utilized for
metabolomics analysis. Interpretation of these data was con-
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FIG. 3. Liver cholesterol and serum LDL/VLDL concentrations in select
strains binned by microvesicular steatosis severity scores. (A) Liver cholesterol
and (B) serum LDL/VLDL evaluated from two drug-resistant strains (steato-
sis severity score in INH-treated animals of 0–1; NON/ShiLtJ, C57BR/cdJ)
and three drug-sensitive strains (microvesicular steatosis severity score in INH-
treated animals of 2–5; NOR/LtJ, DBA/J, and LG/J). All animals were binned
according to low (0–1) or high (2–5) severity scores as done for analysis of
metabolomics data. Data are represented as mean ± SE. *p < 0.05 indicates the
difference between groups as assessed by a Student’s t-test.
ducted using OPLS-DA supervised statistical modeling that
separated vehicle-treated and low-scoring INH-treated animals
from animals with high levels of INH-induced steatosis. Se-
lected variable importance plots were used to identify metabo-
lites that were significantly altered in animals with a high de-
gree of INH-induced steatosis (Table 1). Metabolites involved
in choline metabolism—betaine and phosphocholine—as well
as the antioxidant glutathione were significantly decreased in
the livers of mice that were genetically sensitive to INH-induced
steatosis.
Increased Liver Cholesterol and Reduced Serum VLDL/LDL
Indicate that Choline Reduction May Contribute to Steatosis
Choline metabolism in the liver is essential for the packaging
and export of triglycerides in VLDL (Corbin and Zeisel, 2012).
As a result, decreased choline levels can increase liver choles-
terol while decreasing serum LDL/VLDL (Yao and Vance,
1990). To investigate whether steatosis observed with INH
treatment was related to alterations in choline metabolism,
liver cholesterol and serum LDL/VLDL levels were mea-
sured in INH- and vehicle-treated animals from the three
mouse strains genetically sensitive to INH-induced steatosis
(NOR/LtJ, DBA/2J, and LG/J) and the two strains resistant to
INH-induced steatosis (NON/ShiLtJ, C57BR/cdJ) previously
analyzed in the metabolomics experiment. All animals were
binned based on pathology severity scores (low steatosis: 0–1
or high steatosis: 2–5). Animals with a high steatosis severity
score had significantly increased liver cholesterol (Fig. 3A) and
decreased serum LDL/VLDL (Fig. 3B) relative to animals with
low steatosis severity scores.
FIG. 4. GWA mapping using average fold change in liver triglyceride iden-
tifies QTLs associated with sensitivity to INH-induced microvesicular steatosis.
(A) Manhattan plot of haplotype associations. Black line indicates the threshold
for significance, −log10(p) = 3.5. Circled numbers identify the QTL peaks. (B)
QTL regions identified by GWA mapping. Plin2 (bold) was selected for further
analysis.
Identification of Genetic Variants Associated with
INH-Induced Steatosis
Finally, QTL mapping was performed in order to determine
genomic variants that are associated with the steatosis observed
in susceptible strains following treatment with INH. Because
steatosis severity score is an ordinal and qualitative variable,
mapping was performed using the fold change of the signif-
icantly correlated variable, liver triglyceride levels (Fig. 1C).
Four significantly associated QTLs were identified (Fig. 4A),
and genomic regions were interrogated for biologically relevant
QTGs (Fig. 4B). A candidate gene, Perilipin 2 (Plin2), was iden-
tified within a significant QTL region on chromosome 4. Plin2,
also known as adipophilin, is a protein that coats lipid droplets,
protecting triglycerides from hydrolysis by lipases (Heid et al.,
1998).
SNPs in Plin2 are Associated with INH-Induced Steatosis
SNPs within Plin2 were identified using the Imputed Mouse
SNP Resource (http://csbio.unc.edu/imputation/#tools) (Wang
et al., 2012). For two Plin2 SNPs in linkage with one another,
rs220668384 and rs232770786, INH-induced triglyceride fold
change was significantly lower in strains that are homozygous
for the minor allele (p < 0.05) (Fig. 5A). Plin2 transcript levels
were then examined using the microarray data collected for tran-
scriptomics analysis. Strains homozygous for the minor allele
of these SNPs also had significantly lower INH-induced fold
change in Plin2 mRNA expression levels (p < 0.05) (Fig. 5B).
Finally, adipophilin (which is another name for the protein prod-
uct of Plin2) immunohistochemistry severity scores were exam-
ined by allele call. Interestingly, strains containing the major al-
lele had significantly increased severity scores for adipophilin
staining in INH-treated animals relative to vehicle-treated con-
trols (p < 0.05) (Fig. 5C).
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TABLE 1
Metabolites Significant for Separation of Microvesicular Steatosis Severity Scores
Metabolite p value Incr/Decr Metabolite p value Incr/Decr
2-Aminoadipate <0.050 Incr Lactate <0.100 Decr
3-Hydroxybutyrate <0.100 Decr Leucine <0.100 Decr
Acetate <0.100 Decr Lipoproteins <0.100 Incr




Alanine <0.050 Decr Ornithine <0.100 Decr
Ascorbate <0.010 Decr Phenylalanine <0.005 Decr
Betaine/TMAO <0.050 Decr Serine <0.100 Decr
Cadaverine <0.005 Decr Taurine <0.100 Decr
Fumarate <0.001 Decr Tyrosine <0.100 Decr
Glucose <0.010 Decr Unknown (0.79, 0.83
ppm)
NS Incr
Glutamine <0.100 Incr Unknown (3.16 ppm) <0.005 Incr
Glutathione <0.100 Decr Unknown (3.28 ppm) <0.100 Incr
Glycylproline <0.005 Decr Unsaturated lipids <0.100 Incr
Homoserine <0.100 Incr Valine <0.100 Decr
Isoleucine <0.050 Decr
Notes. Two drug-resistant strains (microvesicular steatosis severity score in INH-treated animals of 0–1; NON/ShiLtJ, C57BR/cdJ) and three drug-sensitive
strains (microvesicular steatosis severity score in INH-treated animals of 2–5; NOR/LtJ, DBA/J, and LG/J) were selected for evaluation of metabolic profiling of
liver tissue. All animals were binned according to low (0–1) or high (2–5) severity score and OPLS-DA analysis was performed to identify the metabolites most
necessary to facilitate separation between the groups. The metabolite increase (Incr) or decrease (Decr) is listed for high microvesicular steatosis severity score
animals in comparison to low microvesicular steatosis severity score animals. Significance was calculated using Student’s t-test. NS: not significant at threshold
of p < 0.1.
FIG. 5. Polymorphisms in Plin2 are associated with INH-induced lipid ac-
cumulation in the liver. (A) Average INH-induced liver triglyceride (TG) fold
change and (B) average INH-induced Plin2 gene expression fold change for
each strain are plotted by genotype. (C) Severity scores for adipophilin (Plin2)
staining evaluated in liver tissue for vehicle-treated (white bars) and INH-treated
(black bars) mice are plotted by genotype. Data are represented as mean ± SE.
*p < 0.05 indicates the difference between groups as assessed by a Student’s
t-test.
DISCUSSION
In this study, genetic variation was shown to play a role in the
development of hepatic microvesicular steatosis caused by INH.
The finding of steatosis in the MDP was not unexpected, given
that rodents have been shown previously to develop steatosis
following administration of INH (Sumner et al., 2010).
Fatty liver changes are often an early sign of liver complica-
tions and can progress to hepatitis and liver necrosis when left
untreated, although subsequent propagating events are typically
required (Day and James, 1998). The possibility exists that pa-
tients receiving INH do initially experience steatosis but have
progressed to overt liver damage by the time a problem is iden-
tified in the clinic. The second “hit” in this case may be the result
of toxic INH metabolites which have been studied and reviewed
elsewhere (Metushi et al., 2011). Of note, starvation is a known
transcriptional activator of CYP2E1, an enzyme involved in the
metabolism of INH intermediates (Hong et al., 1987; Tostmann
et al., 2008). Given that all animals in this study, regardless
of treatment, were fasted prior to initial compound administra-
tion, and again prior to necropsy, the contribution that CYP2E1
induction may have had on the observed phenotype cannot be
determined. Interestingly, previously reported human variants,
like those identified in CYP2E1, were not found to be associated
with susceptibility to steatosis in this mouse model. This may be
the result of weak associations of these factors with INH toxicity
in humans or differences in the mapped phenotypes between the
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studies (i.e., serum aminotransferase levels or clinical outcome
vs. steatosis).
Transcriptomics analysis was performed to better understand
mechanisms underlying the INH-induced steatosis observed in
this study. An interesting finding was the enrichment of the mi-
tochondrial dysfunction pathway among genes that were sig-
nificantly altered by INH treatment but that were not different
between strains sensitive and resistant to INH-induced steatosis.
Previous studies have demonstrated that INH and its hydrazine
metabolite interfere with mitochondrial function (Boelsterli and
Lee, 2014; Lee et al., 2013). Furthermore, there is in vitro ev-
idence to suggest that hydrazine specifically inhibits electron
transport chain complex II activity, but that a second hit (i.e.,
complex I inhibition) would be required to cause hepatocellular
damage (Lee et al., 2013). Whereas some caution is warranted
in extrapolating in vitro findings to whole organisms, our in vivo
study indicates that all strains, regardless of liver response, ex-
hibited INH-induced transcriptional changes in mitochondrial
genes. Of note is that the majority (94%) of genes in the mito-
chondrial dysfunction pathway were upregulated in our model.
Increased levels of mitochondrial genes could be due to mito-
chondrial biogenesis which is both an indication of cell stress
and a mechanism by which cells counteract the effects of mito-
chondrial damage (Degli Esposti et al., 2012).
Although it should be noted that only a single dose and dura-
tion of INH exposure was evaluated, statistical analysis was per-
formed to identify gene expression changes that were not only
different with treatment, but that also differentiated susceptible
and resistant strains independent of treatment. Gene expression
changes that exist under basal conditions that are then further al-
tered with treatment may provide a basis for initiation and prop-
agation of INH-induced steatosis. Of the significantly altered
genes displaying overlap between categorical factors (sensitiv-
ity to INH-induced steatosis and INH treatment itself), interest-
ing candidates relevant to the phenotype were Apoa4, Lamp1,
and Chpt1. Apoa4 is a glycoprotein present on lipoparticles that
is involved in lipid packaging, export, and metabolism (VerH-
ague et al., 2013). Increased levels of Apoa4 in mouse liver en-
hances triglyceride secretion and reduces hepatic lipid content
(VerHague et al., 2013). Whereas INH treatment universally in-
creased Apoa4 levels, this transcript was significantly lower in
strains with INH-induced steatosis relative to those without this
response. Lower Apoa4 levels could limit triglyceride secretion
in these sensitive strains and lead to retention of neutral lipid.
Conversely, although Lamp1 was decreased with treatment,
its levels were higher in strains genetically sensitive to INH-
induced steatosis. Greater transcript abundance of the Lamp1
gene among strains with this response may be particularly in-
teresting given that Lamp1 is an integral membrane glycopro-
tein that mediates LDL uptake in the liver (Hamer et al., 2012).
Lamp1 has also been shown to be upregulated in liver biopsies
of patients with cholesterol ester storage disease (Hulkova and
Elleder, 2012). Additionally, Lamp1 has been shown to regu-
late autophagy via its role in fusing autophagosomes with endo-
somes and lysosomes to facilitate degradation (Corcelle et al.,
2009). The upregulation of mitochondrial genes could be in-
dicative of increased mitochondrial turnover, of which Lamp1
would be a key mediator. Whereas direct evidence of mito-
chondrial autophagy is lacking in the present analysis, warrant-
ing further study, several studies have implicated mitochondrial
stress as a contributing pathway in INH-induced liver injury (re-
viewed in Boelsterli and Lee, 2014).
Chpt1 catalyzes phosphatidylcholine biosynthesis from
CDP-choline. Phosphatidylcholine is an essential component
of VLDL, required for transport of fatty acids out of the liver
(Corbin and Zeisel, 2012). The secretion of VLDL is impaired
when phosphatidylcholine production is restricted, and this
effect has been demonstrated to cause steatosis (Corbin and
Zeisel, 2012). INH is known to deplete vitamin B6 (PLP) ac-
tivity, and vitamin B6 deficiency has been shown to reduce
phosphatidylcholine levels in the liver (She et al., 1995). Chpt1
was decreased in strains sensitive to INH-induced steatosis that
may further decrease phosphatidylcholine levels and promote
triglyceride accumulation.
Further evidence for the involvement of perturbations in
choline metabolism in INH-induced steatosis comes from
metabolomic analysis. Both betaine and phosphocholine,
metabolites that contribute to the production of phosphatidyl-
choline from choline, were decreased in the livers of strains ex-
hibiting high steatosis severity scores. Genetic variation con-
tributes to individual differences in the dietary requirement for
choline (Corbin and Zeisel, 2012). It is plausible that genetic
differences in sensitivity to perturbations in choline metabolism
could contribute to INH-induced steatosis in genetically sensi-
tive individuals. Severe choline deficiency is linked to the pro-
gression of nonalcoholic fatty liver disease through the per-
turbation of mitochondrial bioenergetics and fatty acid beta-
oxidation (Corbin and Zeisel, 2012). This alteration in mito-
chondrial metabolism can lead to mitochondrial dysfunction
and oxidative damage (Corbin and Zeisel, 2012). Although the
metabolite differences observed in the current study may pro-
vide an indication of precursor events in INH-induced injury, it
should be noted that severe liver injury (i.e., necrosis) was not
observed in this study, and further investigation is needed to
identify key downstream events leading to INH-induced hepa-
tocellular death.
Betaine can also support synthesis of methionine and homo-
cysteine, which in turn support synthesis of cysteine and glu-
tathione levels (Mosharov et al., 2000). Therefore, the reduced
levels of glutathione (GSH) observed in mice with a greater de-
gree of steatosis may be due to aberrations in the homocysteine-
dependent transsulfation pathway that contributes to the intra-
cellular GSH pool (Mosharov et al., 2000). Supporting this hy-
pothesis, GSH levels were decreased in the livers of strains
with high steatosis severity scores, and GSH depletion with
INH treatment has been previously reported (Hussain and Fra-
zier, 2002). Ascorbate, which is a complementary antioxidant
to GSH, was also decreased in the livers of mouse strains with
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INH-induced steatosis, potentially providing indirect evidence
of intracellular oxidative stress. Transcriptomic analysis indi-
cated that genes in the D-glucuronate degradation pathway were
upregulated in sensitive strains, independently of treatment. El-
evations in L-gluconate 3-dehydrogenase, for instance, may
drive D-glucoronic acid metabolism toward the pentose phos-
phate pathway instead of toward ascorbate production, thus re-
ducing the basal capacity to buffer against INH-induced oxida-
tive stress in the sensitive strains.
A recent publication examined alterations in the metabolic
profile following the development of INH-induced steatosis
in Sprague Dawley rats (Sumner et al., 2010). Differences in
ascorbate metabolism were identified between rats treated with
INH for 1 day compared with rats treated for 8 days. However,
differences in metabolites downstream of choline metabolism
were not identified (Sumner et al., 2010). This observation may
be explained by species and strain differences between the two
studies. The observation that rats exhibited steatosis, without
reduction in betaine and phosphocholine, suggests that multiple
pathways may contribute to lipid accumulation in the liver fol-
lowing treatment with INH. However, it should be noted that
the extent of INH metabolism and covalent binding with cellu-
lar proteins is more similar between mice and humans than it
is between rats and humans, suggesting that the mouse may be
a more appropriate rodent model to study mechanisms of INH-
induced liver injury (Metushi et al., 2012).
In this study, genetic variations in Plin2 contributing to in-
creased Plin2 expression were also associated with increased
severity of the steatosis outcome following INH treatment. Plin2
is a protein that coats lipid droplets in multiple cell types, in-
cluding hepatocytes, and is important for the regulation lipid
storage and metabolism (Heid et al., 1998). In mice, ablation
of Plin2 results in reduced hepatic triglyceride content, resis-
tance to the development of fatty liver disease, and enhanced
VLDL secretion (McManaman et al., 2013). Conversely, ele-
vated expression of Plin2 has been measured in the livers of ro-
dents on a high fat diet and in patients with fatty liver disease in
the clinic (Motomura et al., 2006). More importantly, polymor-
phisms in Plin2 have been found to affect lipid accumulation,
metabolism, and obesity in humans (Magné et al., 2013). It is
possible that SNPs within Plin2 contribute to elevated Plin2 ex-
pression and enhanced lipid droplet formation with INH treat-
ment. Additional work is necessary to confirm this hypothesis.
In conclusion, this study demonstrated that in genetically di-
verse mice, INH causes microvesicular steatosis in some but not
all mouse strains, suggesting that genetic variation plays a role
in the liver response to this drug. Taken together, a mechanism
is proposed in which INH-induced steatosis is caused by not
one, but multiple events involving inhibition of lipid export by
INH (Fig. 6). These events may contribute to the microvesicular
lipid accumulation that occurs in the liver due to INH exposure
in genetically sensitive individuals.
FIG. 6. Schematic for INH-induced lipid accumulation in genetically sen-
sitive mouse strains. Transcriptomic analysis identified that transcriptional
changes in Apoa4 and Lamp1 are associated with INH-induced microvesicu-
lar steatosis in sensitive strains. As a result, triglyceride levels are increased due
to increased lipoprotein uptake and decreased lipid export. Triglycerides and
sterols are then directed toward packaging in lipoproteins and lipid droplets.
Transcriptomic and metabolomic analysis indicated decreased phosphatidyl-
choline biosynthesis due to lower levels of Chpt1, reducing the capacity for
lipoprotein packing and favoring lipid droplet formation. QTL analysis iden-
tified polymorphisms in Plin2 that may inhibit lipid droplet hydrolysis result-
ing in lipid droplet accumulation and steatosis. Points at which INH may affect
these processes by increasing (red) or decreasing (blue) key metabolites and
transcripts are highlighted.
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